Stocktoria
Zomedica Corp. ZOMDF
Zomedica Corp. (ZOMDF) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $32.0M at a -255.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.99 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.43 |
| Retained earnings / assets | -2.36 |
| EBIT / assets | -0.664 |
| Equity / liabilities | 9.912 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZOMDF | Zomedica Corp. | 3/9 | 1.07 | — | +17.4% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
| VRCA | Verrica Pharmaceuticals Inc. | 5/9 | -19.42 | — | — |
| ETST | Earth Science Tech, Inc. | 4/9 | — | 12.7 | +7.8% |
| SBFM | Sunshine Biopharma Inc. | 4/9 | -1.63 | — | +4.1% |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
FAQ
Is ZOMDF financially healthy?
Zomedica Corp.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ZOMDF pay a dividend?
No, Zomedica Corp. does not currently pay a dividend.
How profitable is ZOMDF?
In FY2025, Zomedica Corp. had a net margin of -255.6% and a return on equity of -70.9%.
Is ZOMDF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zomedica Corp.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.